Literature DB >> 1437509

Future prospects in antiviral therapy.

E H Wiltink1.   

Abstract

Two important stumbling blocks to the development of effective and nontoxic antiviral drugs are the intracellular localization of the virus and the fact that a virus uses host cell functions to multiply. Therefore, new antiviral drugs must act on a virus-specific function. Most currently available useful antiviral drugs are the result of compound screening of large numbers of possible agents. Advances in our understanding of the molecular biology and biochemistry of the viral multiplication cycle and new laboratory techniques for determining the molecular sites of action have now made it possible to develop and screen new antiviral drugs in a more purposeful manner. Another possible option in antiviral therapy is combination therapy using drugs that enhance the therapeutic effect or diminish side-effects. The most promising new antiviral drugs are discussed according to the different steps they affect in the viral multiplication process. Combination therapy is also reviewed.

Mesh:

Substances:

Year:  1992        PMID: 1437509     DOI: 10.1007/bf01962549

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  26 in total

1.  Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro.

Authors:  S M Hammer; J M Gillis
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  Antiviral agents targeted to interact with viral capsid proteins and a possible application to human immunodeficiency virus.

Authors:  M G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

3.  Structural analysis of a series of antiviral agents complexed with human rhinovirus 14.

Authors:  J Badger; I Minor; M J Kremer; M A Oliveira; T J Smith; J P Griffith; D M Guerin; S Krishnaswamy; M Luo; M G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

4.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study.

Authors:  T C Merigan; G Skowron; S A Bozzette; D Richman; R Uttamchandani; M Fischl; R Schooley; M Hirsch; W Soo; C Pettinelli
Journal:  Ann Intern Med       Date:  1989-02-01       Impact factor: 25.391

6.  Aminosugar derivatives as potential anti-human immunodeficiency virus agents.

Authors:  A Karpas; G W Fleet; R A Dwek; S Petursson; S K Namgoong; N G Ramsden; G S Jacob; T W Rademacher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex.

Authors:  W A Carter; D R Strayer; I Brodsky; M Lewin; M G Pellegrino; L Einck; H F Henriques; G L Simon; D M Parenti; R G Scheib
Journal:  Lancet       Date:  1987-06-06       Impact factor: 79.321

Review 8.  Antiviral therapy in human immunodeficiency virus infection.

Authors:  E Sandström
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

9.  Inhibition of HIV progression by dithiocarb. German DTC Study Group.

Authors:  E C Reisinger; P Kern; M Ernst; P Bock; H D Flad; M Dietrich
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

10.  Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus.

Authors:  H T Ho; M J Hitchcock
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.